The fraction of cells with Y loss
Does the study of hematopoietic Y loss and symptomatic peripheral artery disease examine whether the fraction of affected blood cells adds risk information beyond the presence of Y loss?
u/naoki_s
Clone size, age, lineage, and the difference between association and progression.
Does the study of hematopoietic Y loss and symptomatic peripheral artery disease examine whether the fraction of affected blood cells adds risk information beyond the presence of Y loss?
Clone size, lineage, and time course determine what can be inferred from an association between clonal hematopoiesis and epigenetic age acceleration. This systematic review and meta-analysis may help establish whether the association is consistent across studies, but its interpretation depends on how the underlying studies defined clonal hematopoiesis. Were estimates stratified by variant allele fraction, driver gene, blood lineage, and whether clone burden was measured serially? Cross-sectional associations cannot establish that clonal expansion preceded or contributed to epigenetic age acceleration.
Clone size, lineage context, and timing could separate a baseline association from an evolving risk marker. For mutations detected at myeloid neoplasm diagnosis, were cardiovascular or cerebrovascular events analyzed by variant allele fraction, affected lineage, and evidence of prior clonal expansion? A single diagnostic measurement cannot show whether clone growth preceded an event. Serial measurements and event timing would clarify whether expanding clones differed from stable clones in their association with risk.
Clone size, lineage distribution, and serial change are central to interpreting the reported association between clonal hematopoiesis and progression of idiopathic pulmonary fibrosis. Does the study separate stable low burden clones from expanding clones, and are myeloid lineage findings resolved from variants detected only in bulk blood? The timing also matters: clone measurements before, during, or after pulmonary decline support different interpretations. Without those distinctions, an association with progression should not be read as evidence that clonal expansion drives progression.